

9th

International
IVIRMA
Congress

Reproductive
Medicine and Beyond

Virtual
Congress Week
November 15-19,
2021



PROGRAM

INDEX

Welcome Letter.....	03
Committee.....	04
Program Overview.....	05
Scientific Program.....	06
Sustainable Congress.....	11
General Information.....	13
Industry-Sponsored Symposium.....	15
Supporters.....	19
Supporters Corporate Information.....	21



International
VIRMA
Congress

Reproductive
Medicine and Beyond

Virtual
Congress Week
November 15-19,
2021





WELCOME LETTER

Dear friends and colleagues,

At a time when health and science have proven to be the driving force of the world, at IVIRMA we would like to take a step forward to continue sharing findings and knowledge.

Scientific meetings are essential for the development of medicine and ours is no exception.

We are therefore delighted to announce the celebration of the 9th IVIRMA International Congress (November 15th-19th, 2021), a virtual scientific event organised with great attention to detail and huge opportunities for all.

The sessions of the scientific program of the IVIRMA Learning Week have been adapted to the new way of e-learning.

One of the main novelties of this meeting is that it will be more inclusive and holistic, as, just like in previous meetings, **we will have sections focussing on the works of embryologists**, as well as professionals from the fields of psychology and other key collectives which are essential in the management of the infertile patient.

The main focus of these scientific meetings will be debates on up-to-the-minute topics such as the preservation of fertility, non-invasive embryo assessment, immunological treatments, or the importance of the endometrium in reproductive success.

Though the **9th IVIRMA International Congress** has been envisaged as a meeting where to learn, it will be a forum not only for the sharing and exchanging of experiences but also for fostering new contacts to allow us to further progress in our speciality. We return virtually, so that success may be on our side, both in our clinics and laboratories.

Our aim is to continue **providing top-level reproductive medicine congresses**, addressing cutting-edge topics in this continuously evolving field of human reproduction, and doing so counting with the most reputable international speakers worldwide.

HONORARY PRESIDENTS

Prof. Antonio Pellicer

Prof. José Remohí

Prof. Richard Scott



COMMITTEE

HONORARY PRESIDENTS

Prof. Antonio Pellicer

Prof. José Remohí

Prof. Richard Scott

EXECUTIVE DIRECTOR

Mr. Miguel Tablado

SCIENTIFIC COMMITTEE

Chairman

Prof. Juan Antonio García-Velasco

Scientific Director

Prof. Emre Seli

Scientific Secretary

Mrs. María Delgado

Scientific Committee Members

Prof. José Bellver

Dr. César Díaz

Prof. Jason Franasiak

Dr. Nicolás Garrido

Dr. Jim Hotaling

Prof. Juan Antonio García-Velasco

Dr. Marcos Meseguer

Prof. Antonio Pellicer

Prof. José Remohí

Dr. Antonio Requena

Prof. Richard Scott

Prof. Emre Seli

Dr. Dagan Wells



PROGRAM OVERVIEW

Simultaneous translation available:



	MONDAY 15	TUESDAY 16	WEDNESDAY 17	THURSDAY 18	FRIDAY 19
16:30 17:00					
17:00 17:20	FUTURE PROFESSIONALS How to start doing research	INDUSTRY SUPPORTED SYMPOSIUM	FUTURE PROFESSIONALS Basic IVF lab fundamentals for starting embryologists	INDUSTRY SUPPORTED SYMPOSIUM	FUTURE PROFESSIONALS What ART can do for your patients: a summary for gynecologists
17:20 17:30	Opening Ceremony				
17:30 18:00	KEYNOTE LECTURE The future of embryo selection		KEYNOTE LECTURE The role of mitochondria on ovarian aging		KEYNOTE LECTURE New therapeutic options in women with POI
18:00 18:30	EXPERTS DEBATE Elevation of progesterone at the end of the follicular phase is critical	INDUSTRY SUPPORTED SYMPOSIUM	EXPERTS DEBATE Preeclampsia in ART patients	INDUSTRY SUPPORTED SYMPOSIUM	EXPERTS DEBATE Routine Immune modulation in IVF
18:30 19:00	EXPERTS DEBATE Fertility preservation: oocytes are preferred to ovarian tissue		EXPERTS DEBATE Recurrent implantation failure		EXPERTS DEBATE Non invasive PGT-A: are we ready?
19:00 19:30	EXPERTS DEBATE HPV Semen Infection What is new in the genomic era in male infertility	INDUSTRY SUPPORTED SYMPOSIUM	EXPERTS DEBATE Chronic endometritis compromises IVF success rates	INDUSTRY SUPPORTED SYMPOSIUM	EXPERTS DEBATE IVF labs and embryo selection will be based on Artificial intelligence
19:30 20:00					Closing



SCIENTIFIC PROGRAM

MONDAY 15TH NOVEMBER

17:00-17:20

FUTURE PROFESSIONALS

How to start doing research

Chair: Juan A. García Velasco, *Spain*

Speaker:

Nicolás Garrido, *Spain*

17:20-17:30

Opening Ceremony

17:30-18:00

KEYNOTE LECTURE

The future of embryo selection

Chair: Antonio Pellicer, *Spain*

Speaker:

Richard Scott, *USA*

18:00-18:30

EXPERTS DEBATE

Elevation of progesterone at the end of the follicular phase is critical.

Chair: Ernesto Bosch, *Spain*

Speakers:

Yes - Nikos Polyzos, *Spain*

No - Peter Humaidan, *Denmark*

18:30-19:00

EXPERTS DEBATE

Fertility preservation: oocytes are preferred to ovarian tissue

Chair: Anabel Salazar, *Spain*

Speakers:

Yes - Ana Cobo, *Spain*

No - Claus Ydig Andersen, *Denmark*

19:00-19:30

HPV Semen Infection

Chair: Alberto Pacheco, *Spain*

Speaker:

Carlo Foresta, *Italy*

What is new in the genomic era in male infertility

Chair: Alberto Pacheco, *Spain*

Speaker:

Craig Niederberger, *USA*



SCIENTIFIC PROGRAM

TUESDAY 16TH NOVEMBER

17:30-18:30

TIME FOR A GENETIC POINT OF VIEW

Chair: Fernando Bronet, *Spain*

Speakers:

- ▶ **Factors affecting genetic outcome after trophoctoderm biopsy**
Danilo Cimadomo, *Italy*
- ▶ **Aneuploid human embryos: from genotype to phenotype**
Marta Shabazi, *Spain*
- ▶ **Automation and the future of the embryologist**
Rita Vassena, *Italy*

18:30-20:00

WORKSHOP FAMILY DOCTORS

Chair: Agustín Ballesteros, *Spain*

Speakers:

- ▶ **Basic Fertility workup: Individualization based on the age of the couple**
Manuel Fernández, *Spain*
- ▶ **What does ART offer me when I want to have a child but I cannot**
Gemma Castellón, *Spain*
- ▶ **What are my choices if I would like to postpone maternity**
Javier Domingo, *Spain*





SCIENTIFIC PROGRAM

WEDNESDAY 17TH NOVEMBER

17:00-17:30

FUTURE PROFESSIONALS

Basic IVF lab fundamentals for starting embryologists

Chair: Mireia Florensa, *Spain*

Speaker:

David Agudo, *Spain*

17:30-18:00

KEYNOTE LECTURE

The role of mitochondria on ovarian aging

Chair: Dagan Wells, *UK*

Speaker:

Emre Seli, *USA*

18:00-18:30

EXPERTS DEBATE

Preeclampsia in ART patients

Chair: Sergio Soares, *Portugal*

Speakers:

▶ **Preeclampsia prevention with ultrasound/biomarker**

Vicente Serra, *Spain*

▶ **Strategies in ART to prevent preeclampsia**

José Bellver, *Spain*

18:30-19:00

Recurrent implantation failure

Chair: José Serna, *Spain*

Speakers:

▶ **It's the embryo**

Paul Pirtea, *France*

▶ **It's the endometrium**

Joop Laven, *The Netherlands*

19:00-19:30

Chronic endometritis compromises IVF success rates

Chair: Elkin Muñoz, *Spain*

Speakers:

Yes - Ettore Cicinelli, *Italy*

No - Shari Mackens, *Belgium*



SCIENTIFIC PROGRAM

THURSDAY 18TH NOVEMBER

17:30-18:30

WORKSHOP PSYCHOLOGISTS

Chair: Antonio Requena, *Spain*

Speakers:

▶ **Preventing drop-out**

Diana Guerra, *Spain*

▶ **Impact of underlying stress in infertility**

Diana C. Santa-Cruz, *Spain*

▶ **End of anonymity: stepping into the dawn of communication and a new paradigm in gamete donor counseling**

Andrea Braverman, *USA*

9th



SCIENTIFIC PROGRAM

FRIDAY 19TH NOVEMBER

17:00-17:30

FUTURE PROFESSIONALS

What ART can do for your patients: a summary for gynecologists

Chair: Alfonso Bermejo, *Spain*

Speaker:

Anabel Salazar, *Spain*

17:30-18:00

KEYNOTE LECTURE

New therapeutic options in women with POI

Chair: Emre Seli, *USA*

Speaker:

Antonio Pellicer, *Spain*

18:00-18:30

EXPERTS DEBATE

Routine Immune modulation in IVF

Chair: Marcos Ferrando, *Spain*

Speakers:

Useful - Diana Alecsandru, *Spain*

Useless - Nick Macklon, *UK*

18:30-19:00

Non invasive PGT-A: are we ready

Chair: Nicolás Prados, *Spain*

Speakers:

Yes - Carmen Rubio, *Spain*

No - Dagan Wells, *UK*

19:00-19:30

IVF labs and embryo selection will be based on Artificial intelligence

Chair: María José de los Santos, *Spain*

Speakers:

Yes - Marcos Meseguer, *Spain*

No - Giovanni Coticchio, *Italy*



SUSTAINABLE CONGRESS

The current complex environment requires multilateral responses from all sectors when it comes to tackling social, environmental, and economic challenges. The 9th edition of the International IVIRMA Congress will have a strong sustainable impact, as its organisation and development will leverage technology, digital innovation, and health prevention.

Why are we committed to sustainability?

In our company, sustainability is understood as a way of doing business with a conscience, which results from listening to our stakeholders. Any event we organise is managed from this three-pronged approach: social, economic, and environmental.

As far as sustainability is concerned, we are convinced it should be a cross-cutting issue in the management of Reproductive Medicine, as well as have a positive impact on Society, reducing the carbon footprint and focusing on Health in all its forms.

Although we innovate and go one step further every year in our social and environmental commitments, there are certain guidelines governing our activity in terms of sustainability. Please find in the following video an example of what the IVIRMA Sustainable Congress 2019 was like: [web](#)

9th International IVIRMA Congress, a green and healthy congress

From your computer...

There is no turning back on the road to digitalisation at IVIRMA. At our company we are facing this paradigm shift with our homework done and with the conviction that digital transformation is the present and the future of our company. Therefore, this year, within the current social and economic context, we are committed to holding an online congress, backed by our extensive experience in digital platforms and online learning.

Experience in digital platforms and online learning. Our robust technical infrastructure in the area of Global Education allows us to offer you an innovative Congress without leaving your home, breaking down physical barriers and enabling work-life balance at a time when necessity reigns supreme. **Without the need to travel and with a lower environmental impact...**





IVIRMA International Conference welcomes more than 1,400 attendees from over 70 countries.

- ▶ The absence of travelling results in a drastic reduction of the carbon footprint.
- ▶ The Zero Waste objective, which has always been present at our congresses, is particularly relevant in this ninth edition, due to the digitalisation of the congress and elimination of all physical materials, both those related to papers and stage design.
- ▶ The elimination of plastic in all its forms is a given fact in this 9th edition.
- ▶ Optimising energy consumption is one of our energy priorities. The event's online format leads to a significant reduction in electricity consumption for the organisation and running of the event.

All these actions allow us to mitigate our environmental impact and strengthen our commitment to sustainability in the short, medium, and long term.

Committed to health...

The 2030 Agenda, adopted by the United Nations in 2015, is an action plan for people, our planet and prosperity, while also intending to strengthen universal peace and access to justice, by fostering partnerships.

The Agenda sets out 17 Sustainable Development Goals (SDGs) covering the economic, social, and environmental spheres and incorporating global social challenges.

With the aim of being part of these key agents for development and aligning ourselves with the 2030 Agenda, we have identified the significant SDGs based on their prioritisation by the organisation and IVIRMA's stakeholders. This process was carried out by means of a survey completed by more than 200 people, including stakeholders and key people at IVIRMA. SDG 3 "Ensure healthy lives and promote well-being for all at all ages" is one of the goals designated a priority. For this reason, the Sustainability Plan for this Congress will focus on this goal.

Health above all

During 2020 and 2021, the effectiveness of IVIRMA's risk management approach was proven following the declaration of the COVID-19 pandemic, as we declared the Health and Safety of our stakeholders a key element of our work. Our commitment to a safe and healthy environment is embodied in this online Congress, thus helping to avoid potential and unnecessary risks as well as continuing to put Health above anything else.



GENERAL INFORMATION

TECHNICAL SECRETARIAT

GRUPO PACIFICO
The power of meeting

Marià Cubí 4, 08006 Barcelona
Phone: +34 93 238 87 77
congress2021@ivirma.com

CONGRESS WEBSITE

<https://ivirmacongress.com/>

ACCESS

In order to access the 9th International IVIRMA Congress - Virtual, it will be necessary to have previously completed the registration. The access to the virtual platform will be available from November 15th.

The Technical Secretariat will provide you in advance with the access link, as well as username and password to access the virtual Congress.





CERTIFICATES

ATTENDANCE

Attendance certificates will be sent in electronic format upon completion of the Congress.

CME CERTIFICATE

https://ivirmacongress.com/images/PROGRAMA_IVI_2021.pdf

EACCME® credits

EACCME® Accreditation of the 9th International IVIRMA Congress, Virtual, Spain, 15/11/2021-19/11/2021

The **9th International IVIRMA Congress, Virtual, Spain, 15/11/2021-19/11/2021** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA

Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Please find below the breakdown of ECMEC®s per day:

15.11.2021 - 2.00

16.11.2021 - 2.00

17.11.2021 - 2.00

18.11.2021 - 1.00

19.11.2021 - 2.00

Industry sponsored sessions taking place on 16 and 18 of November are not viable for accreditation. Only the participation to the workshops can award participants for EACCME credits for those days.



INDUSTRY-SPONSORED SYMPOSIUM

TUESDAY 16TH NOVEMBER

16.30-17.30h



Management of Poor Responders: Exploring Therapeutic Considerations

Chairman: Gaurang Daftary
Global Scientific Vice President, RMMH, Ferring Pharmaceuticals

▶ **The Poor Responder: Evolving our understanding**

Christine Wyns

Head of the Cliniques Universitaires Saint-Luc's Gynaecology and Andrology Department

Medical Director of the Reproductive Tissue and Cell Bank.

Professor at Université Catholique de Louvain.

▶ **The Poor Responder: Protocol considerations**

Juan Antonio García Velasco

Director of IVI Madrid.

Professor of Obstetrics and Gynaecology at Rey Juan Carlos University, Madrid, *Spain*

▶ **The Poor Responder: Clinical Practice**

Wyns & García Velasco

17.30-18.30h



Caring Innovation

The era of individual luteal phase support (iLPS) has begun

Chairman: Joaquín Llácer

Medical Director Ginefiv-GeneraLife *Spain*

▶ **Importance of progesterone levels during implantation**

Dominique De Ziegler

University Consultant at Foch Hospital, *France*

▶ **Beyond implantation.**

Progesterone levels for maintenance of pregnancy

Elena Labarta

Gynaecologist specialized in assisted reproduction. IVIRMA, *Spain*



INDUSTRY-SPONSORED SYMPOSIUM

TUESDAY 16TH NOVEMBER

18.30-19.30h

MERCK

Personalized Management of patients in reproductive medicine

Moderator:

Monica Lispi, GMA Merck

- ▶ **Speaking about success in Normoresponders**
Filippo Ubaldi
- ▶ **Who may benefit of rLH?**
Shahar Kol

9th



INDUSTRY-SPONSORED SYMPOSIUM

THURSDAY 18TH NOVEMBER

16.30-17.30h



GEDEON RICHTER

How Artificial Intelligence could improve IVF utilization>Welcome

Chairman: Nick Macklon

▶ **Overview of artificial Intelligence in Healthcare**

Ignacio H. Medrano
Founder & Chief Medical Officer at SAVANA

▶ **Clinical integration into IVF of Artificial Intelligence and Machine learning**

Ernesto Bosch
Medical Director IVIRMA Valencia

▶ **Conclusions**

Nick Macklon

17.30-18.30h



Organon Introduction (10')

Keith Gordon

Executive Global Director of Fertility Medical affairs in Organon
(Chairman)

▶ **Customizing the approach of ovarian stimulation for every patient category**

Christophe Blockeel
Medical Director Centre for Reproductive Medicine, UZ Brussel
Q&A (10'-15')

18.30-19.30h



CooperSurgical®

Why an electronic witnessing system is valued as an essential team player by both clinics and patients

▶ **The Lab Managers perspective on why RI Witness should be considered a "team player" in the lab**

Albert Obradors,
Founder and Lab Director
FIV Obradors

▶ **The patient perspective on the benefits of an electronic witnessing system**

Stephen Troup
Consultant Reproductive Scientist

Changing reproductive health care for generations to come





SUPPORTERS

PRESIDENTIAL



GEDEON RICHTER

GOLD



SILVER





innovation and curiosity to move forward

We are partnering with you today to meet
the needs that will anticipate tomorrow's
challenges

Our present is the future of patients

MERCK
connecting details for life

MERCK



SUPPORTERS CORPORATE INFORMATION

PRESIDENTIAL



FERRING PHARMACEUTICALS

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.



Company address:

Ferring International Center S.A.
Ch. de la Vergognausaz 50
1162 Saint-Prex
Switzerland



Company E-mail:

laura.galvis@ferring.com



Web:

Learn more at
www.ferring.com,
or connect with us on
LinkedIn, Instagram,
Facebook, Twitter and
YouTube



Company Phone Number:

+41 58 301 00 00



Company Fax Number:

+41 58 301 00 10



GEDEON RICHTER

GEDEON RICHTER

Gedeon Richter Plc., headquartered in Budapest, Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China and Latin America. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Neuroscience and Cardiovascular medicine. Having the largest R&D unit in Central Eastern Europe and building upon its original focus in CNS disorders and its widely acknowledged steroid chemistry expertise, Richter has also become a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.



Company address:

Gyömrői út 19-21- 1103
Budapest, Hungary



Company E-mail:

marco.menabrito@preglem.com



Company Phone Number:

+41 22 884 0395



Web:

<https://www.gedeonrichter.com/en>



SUPPORTERS

CORPORATE INFORMATION

GOLD



MERCK SLU

Merck is a leading science and technology company, active in Healthcare, Life Science and Electronics. Around 58,000 employees work all around the world to contribute to a sustainable human progress through innovation and aligned with EU green deal, tackling challenges like accelerating scientific discovery, personalized health, lack of resources, and more efficient connectivity.

Merck Spain has three manufacturing sites: biotechnological, pharmaceutical and chemical. The company is committed, together with other social and business agents, to respond to local economic and social challenges, as the development of female talent, the promotion of scientific excellence and the changes that technology and innovation introduce in our society.

Merck (Merck KGaA) is named this way around the world, except in the United States and Canada, where it operates under the EMD brand



Company address:

MARIA DE MOLINA 40, 28006 MADRID, SPAIN



Company Phone Number:

+91 745 44 00



Company Fax Number:

+91 745 44 44



Company E-mail:

comunicacion@merckgroup.com



Web:

www.merck.es



SUPPORTERS

CORPORATE INFORMATION

GOLD



ORGANON

We believe in a better and healthier every day for every woman. And we understand that women are foundational to a healthier world. As a new company, we will begin by listening to women's healthcare needs, big and small, enabling us to develop treatments tailored to them – because we know there is so much more we can do for women and their health. We build upon our strong foundation of more than 60 medicines and other products across a range of areas including reproductive health, heart disease, dermatology, allergies and asthma.



Company address:

Paseo de la Castellana, nº 77_28046 MADRID



Company Phone Number: +34 91 591 1279



Company Fax Number: n/a



Company E-mail: organon_info@organon.com



Web: www.organon.com



THERAMEX

Theramex is a global specialty pharmaceutical company solely committed to supporting the health needs of women. By working closely with our partners and healthcare professionals, we provide a diverse portfolio of treatments that help women through each of their life stages. Theramex brings new and innovative solutions for contraception, fertility, menopause and osteoporosis.



Company address:

C/ Martínez Villergas, 52, Edificio C, 2º Izq. Madrid, 28027



Company Phone Number: +34 911 143 487



Company E-mail: customerservice.es@theramex.com



Web: www.theramex.es

The next big advancement in women's health



Organon, a new global women's healthcare company.
Our commitment is listening to every woman,
everywhere, so that we can better address her health
needs.

Because health begins when we hear her

Discover more in www.HereForHerHealth.com



ORGANON

Follow us:

Twitter [@OrganonEspana](https://twitter.com/OrganonEspana)

LinkedIn [Organon España](https://www.linkedin.com/company/organon-espana)

And on our website for HealthCare Professionals:

www.organonconnect.es



SUPPORTERS

CORPORATE INFORMATION

SILVER



COOK MEDICAL

Cook Medical has been collaborating with physicians and researchers for over 50 years to create minimally invasive medical devices.

Since 1980, Cook's Reproductive Health division has manufactured products for diagnostic imaging, assisted reproduction, maternal-fetal medicine, obstetrics, and gynaecology.

Cook Reproductive Health is committed to advancing education, research, and collaboration with physicians in order to enhance patient care for women and men throughout their reproductive lives.

For more information, visit www.cookmedical.com/rh.



CooperSurgical®

COOPERSURGICAL

At CooperSurgical, we continue to push the boundaries to build a better journey for all, to change fertility care for generations to come.

This means changing fertility standards, the fertility journey, and providing better access globally to fertility treatments.

Delivering innovative solutions, working closely together to standardize, optimize and automatize clinical workflows, and sharing best practices, we can help clinics reach higher levels of efficiency that help change fertility care.



Company address:


Trumbull, CT, United States



Web:

<https://fertility.coopersurgical.com/>

Coloque embriones
con confianza.



Guardia™
EMBRYO TRANSFER CATHETERS



SUPPORTERS CORPORATE INFORMATION

SILVER



Caring Innovation

IBSA

IBSA is a multinational pharmaceutical company headquartered in Lugano, Switzerland. The company operates in more than 80 countries and 5 continents with 16 subsidiaries in Europe, China and in USA, employing over 1.600 people. IBSA holds 82 patent families and many others in development with a diversified portfolio covering 10 therapeutic areas. It is one of the fourth largest operators worldwide in the area of Reproductive Medicine and one of the world's leaders in hyaluronic acid-based products.



Email address:

cc@ibsa.ch



Company Fax Number:

Fax +41 58 360 16 77
CHE-116.345.623 IVA



Headquarters:

Via del Piano 29 | CH-6915
Pambio-Noranco | Tel. +41 58
360 10 00



Web:

www.ibsa-swiss
www.ibsagroup.com



Manufacturing and Technical Operations:

Via al Ponte 13, P.O. Box 622
CH-6900 Massagno



JUNO GENETICS

Juno Genetics is a state-of-the-art laboratory specialising in genetic testing. Our mission is to provide clinically useful information of the highest quality for couples who are planning to start a family, patients undergoing fertility treatments, and for women who are already pregnant.

The innovative tests offered by Juno Genetics are amongst the most technologically advanced and accurate available anywhere in the world.

The cutting-edge tests provided by Juno are the result of world-class research carried out by an internationally renowned team of scientists.



Company address:

Winchester House, Heatley
Road, Oxford Science Park,
Oxford OX4 4GE



Company E-mail:

supportspain@junogenetics.com



Company Phone Number:

+44 203 743 1944



Web:

www.junogenetics.com



SUPPORTERS

CORPORATE INFORMATION

SILVER



KITAZATO CORPORATION

Kitazato Corporation is a global company based in Japan, dedicated to the assisted reproductive technologies field.

World leaders in vitrification of human specimens, we perform extensive research, develop, manufacture and market medical devices and media to support a wide range of fertility treatments, from IUI to PGT.



Company address:

100-10 Yanagishima, Fuji, Shizuoka 416-0932 Japan



Company Phone Number: +81 545-65-7122



Company Fax Number: +81 545-65-7128



Company E-mail: contact@kitazato.co.jp



Web: www.kitazato-ivf.com



KARL STORZ ENDOSCOPIA IBÉRICA SA

KARL STORZ is a leading provider of reusable products for endoscopy and related medical technologies. A family-owned company headquartered in Tuttlingen, Germany, KARL STORZ offers a continually expanding product range encompassing and significant advances in surgical technology including medical informatics solutions, new technologies for natural orifice and single-incision surgical techniques, and miniature instrumentation for minilaparoscopic treatment options, among others.



Company address: Parque empresarial San Fernando, Edificio Munich. Planta baja. 28830, madrid



Company Phone Number: +34 916771051



Company E-mail: marketing-es@karlstorz.com



Web:

<https://www.karlstorz.com/de/es/index.htm?countryselect=de&target=&rdePwdDays=9223372036854775807>



SUPPORTERS

CORPORATE INFORMATION

SILVER



REFERENCE LABORATORY GENETICS

Since its foundation in 1975, Reference Laboratory has established itself as one of the leading European laboratories in special analysis. We are the largest laboratory in Europe (15.000m2) and we currently collaborate with more than 400 hospitals and over 1,000 laboratories around the world. Reference Laboratory Genetics is our Genetics and Molecular Diagnostics Division.



Company address:

Pablo Iglesias 57, 08908, Hospitalet de Llobregat, Barcelona



Company Phone Number: 0034 93 259 37 00



Company Fax Number: 0034 93 284 50 00



Company E-mail: genetics@referencelaboratory.es



Web: www.reflabgenetics.com



VITROLIFE

Vitrolife's vision is to fulfil the dream of having a baby. We support our customers to achieve successful treatment outcomes by providing valued solutions and services for assisted reproduction. Together. All the way.



Company address:

Gustaf Werners gata 2, 421 32 Västra Frölunda, Sweden



Company Phone Number: +46 31 721 80 00



Company Fax Number: +46 31 721 80 99



Company E-mail: info@vitrolife.com



Web: www.vitrolife.com

9th



International
IVIRMA
Congress

Reproductive
Medicine and Beyond

Virtual
Congress Week
November 15-19,
2021

www.ivirmacongress.com
congress2021@ivirma.com

